Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV

Oxford Immunotec Global PLC

, a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patient has been enrolled in the REACT study. The REACT study, which focuses on stem cell transplant patients, is the second of two pivotal clinical trials designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT®.CMV test. "We are happy to announce that the enrollment process is underway, on schedule, for our REACT study," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We remain excited about the potential clinical and economic value of our T-SPOT.CMV test."